Thrombolytic Therapy: Current Status

New England Journal of Medicine

Volumn 318, Issue 24, 1988, Pages 1585-1595

  Marder, Victor J ^a   Sherry, Sol ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLASMINOGEN ACTIVATOR; PROUROKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; DEEP VEIN THROMBOSIS; HEART INFARCTION; HUMAN; LUNG EMBOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW;

ARTERIAL OCCLUSIVE DISEASES; FIBRINOLYTIC AGENTS; HUMAN; MYOCARDIAL INFARCTION; PULMONARY EMBOLISM; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOPHLEBITIS; THROMBOSIS;

EID: 0023891018     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198806163182406     Document Type: Review

References (121)

1. Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acylenzymes: a new approach to thrombolytic therapy. Nature 1981; 290: 505–8.
2. Collen D. Human tissue-type plasminogen activator: from the laboratory to the bedside. Circulation 1985; 72: 18–20.
3. Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1982; 69: 573–80.
4. Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981; 291: 590–1.
5. Marder VJ, Budzynski AZ. Fibrinogen and its derivatives, hereditary and acquired abnormalities. Schweiz Med Wochenschr 1974; 104: 1338–42.
6. Mentzer RL, Budzynski AZ, Sherry S. High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation. Am J Cardiol 1986; 57: 1220–6.
7. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. J Clin Invest 1987; 79: 1642–7.
8. Ferres H. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex. Drugs 1987; 33: Suppl 3: 33–50.
9. Hess H, Ingrisch H, Mietaschk A, Rath H. Local low-dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med 1982; 307: 1627–30.
10. Spann JF, Sherry S. Coronary thrombolysis for evolving myocardial infarction. Drugs 1984; 28: 465–83.
11. Marder VJ, Francis CW. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. Prog Hemost Thromb 1984; 7: 325–56.
12. Kennedy JW, Ritchie JL, Davis KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477–82.
13. Marder VJ. Pharmacology of thrombolytic agents: implications for therapy of coronary artery thrombosis. Circulation 1983; 68: Suppl I: I2–15.
14. Dotter CT, Rösch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111: 31–7.
15. Bode C, Matsueda GR, Hui KY, Haber E. Antibody-direction urokinase: a specific fibrinolytic agent. Science 1985; 229: 765–7.
16. Duckert F, Müller G, Nyman D, et al. Treatment of deep vein thrombosis with streptokinase. Br Med J 1975; 1: 479–81.
17. Marder VJ. Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. Am J Med 1987; 83(2A): 15–9.
18. Burket MW, Smith MR, Walsh TE, Brewster PS, Fraker TD Jr. Relation of effectiveness of intracoronary thrombolysis in acute myocardial infarction to systemic thrombolytic state. Am J Cardiol 1985; 56: 441–4.
19. Kolts RL, Keuhner ME, Swanson MK, Carlson RD, Myers WO, Friedenberg WR. Local intra-arterial streptokinase therapy for acute peripheral arterial occlusions: should thrombolytic therapy replace embolectomy? Am Surg 1985; 51: 381–7.
20. Sicard GA, Schier JJ, Totty WG, et al. Thrombolytic therapy for acute arterial occlusion. J Vasc Surg 1985; 2: 65–78.
21. Sherry S. Tissue plasminogen activator (t-PA): will it fulfill its promise? N Engl J Med 1985; 313: 1014–17.
22. Goldhaber SZ, Vaughan DE, Markis JE, et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986; 2: 886–9.
23. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J 1974; 1: 343–7.
24. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203: 465–70.
25. Urokinase-Pulmonary Embolism Trial: Phase I results: a cooperative study. JAMA 1970; 214: 2163–72.
26. Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303: 842–5.
27. Schwarz F, Stehr H, Zimmermann R, Manthey J, Kubier W. Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism. Circulation 1985; 71: 117–23.
28. de Soyza NDB, Murphy ML. Persistent post-embolic pulmonary hypertension. Chest 1972; 62: 665–8.
29. Paraskos JA, Adelstein SJ, Smith RE, et al. Late prognosis of acute pulmonary embolism. N Engl J Med 1973; 289: 55–8.
30. Miller GR, Hall RJ, Paneth M. Pulmonary embolectomy, heparin, and streptokinase: their place in the treatment of acute massive pulmonary embolism. Am Heart J 1977; 93: 568–74.
31. Immelman EJ, Jeffery PC The postphlebitic syndrome: pathophysiology, prevention and management. Clin Chest Med 1984; 5: 537–50.
32. Robertson BR. On thrombosis, thrombolysis and fibrinolysis. Acta Chir Scand [Suppl] 1971; 421: 1–51.
33. Arnesen H, Heilo A, Jakobsen E, Ly B, Skaga E. A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand 1978; 203: 457–63.
34. Trubestein G, Brecht T, Ludwig M, Brecht G, Etzel F. Fibrinolytische therapie mit streptokinase and urokinase bei tiefer venenthrombose. In: Trubestein G, Etzel F, eds. International Symposium on Fibrinolytic Therapy, Bonn 1982. Stuttgart: Shattauer Verlag 1983:193–201.
35. Bauer G. A roentgenological and clinical study of the sequels of thrombosis. Acta Chir Scand (Suppl] 1942; 74: 1–126.
36. O'Donnell TF Jr, Browse NL, Burnand KG, Thomas ML. The socioeconomic effects of an ileofemoral thrombosis. J Surg Res 1977; 22: 483–8.
37. Amesen H, H0iseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis. Acta Med Scand 1982; 211: 65–8.
38. Johansson L, Nylander G, Hedner V, Nilsson IM. Comparison of streptokinase with heparin: late results in the treatment of deep vein thrombosis. Acta Med Scand 1979; 206: 93–8.
39. Elliot MS, Immelman EJ, Jeffery P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979; 66: 838–43.
40. Watz R, Savidge GF. Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. Acta Med Scand 1979; 205: 293–8.
41. Common HH, Seaman AJ, Rö sch J, Porter JM, Dotter CT. Deep vein thrombosis treated with streptokinase or heparin: follow-up of a randomized study. Angiology 1976; 27: 645–54.
42. Kakkar VV, Howe CT, Laws JW, Flanc C Late results of treatment of deep vein thrombosis. Br Med J 1969; 1: 810–1.
43. Kakkar VV, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis: a prospective study. Am J Surg 1985; 150(4A):54–63.
44. Greenwood LH, Yrizarry JM, Hallatt GW Jr, Scoville GS Jr. Urokinase treatment of Budd-Chiari syndrome. AJR 1983; 141: 1057–9.
45. Sholar PW, Bell WR. Thrombolytic therapy of inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria. Ann Intern Med 1985; 103: 539–41.
46. Rowe JM, Rasmussen RL, Mader SL, DiMarco PL, Cockett ATK, Marder VJ. Successful thrombolytic therapy in two patients with renal vein thrombosis. Am J Med 1984; 77: 1111–4.
47. Fairer JF, Goodwin WE. Treatment of priapism: comparison of methods in fifteen cases. J Urol 1961; 86: 768–75.
48. Glynn MF, Langer B, Jeejeebhoy KN. Therapy for thrombotic occlusion of long-term intravenous alimentation catheters. JPEN 1980; 4: 387–90.
49. Druy EM, Trout HH III, Giordano JM, Hix WR. Lytic therapy in the treatment of axillary and subclavian vein thrombosis. J Vase Surg 1985; 2: 821–7.
50. Smith NL, Ravo B, Soroff HS, Khan SA. Successful fibrinolytic therapy for superior vena cava thrombosis secondary to long-term total parenteral nutrition. JPEN 1985; 9: 55–7.
51. Shenoy MM, Friedman SA, Dhar S, Berman P. Streptokinase lysis of intraventricular thrombus and pulmonary emboli with resolution of acquired intracardiac shunt. Ann Intern Med 1985; 103: 65–6.
52. Kohner EM, Pettit JE, Hamilton AM, Bulpitt CJ, Dollery CT. Streptokinase in central retinal vein occlusion: a controlled clinical trial. Br Med J 1976; 1: 550–3.
53. Sellors PJ, Kanski JJ, Watson DM. Intravitreal urokinase in the management of vitreous haemorrhage. Trans Ophthalmol Soc UK 1974; 94: 591–8.
54. Elliot MS, Immelman EJ, Jeffery P, et al. The role of thrombolytic therapy in the management of phlegmasia caerulea dolens. Br J Surg 1979; 66: 422–4.
55. Rubenstein M, Creger WP. Successful streptokinase therapy for catheter-induced subclavian vein thrombosis. Arch Intern Med 1980; 140: 1370–1.
56. Amery A, Deloof W, Vermylen J, Verstraete M. Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. Br Med J 1970; 4: 639–44.
57. Martin M. Thrombolytic therapy in arterial thromboembolism. Prog Cardiovasc Dis 1979; 21: 351–74.
58. Verstraete M. Biochemical and clinical aspects of thrombolysis. Semin Hematol 1978; 15: 35–54.
59. Belkin M, Belkin B, Bucknam CA, Straut JJ, Lowe R. Intra-arterial fibrinolytic therapy: efficacy of streptokinase vs. urokinase. Arch Surg 1986; 121: 769–73.
60. McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. AJR 1985; 144: 769–75.
61. Flickinger EG, Johnsrude IS, Ogbum NL, Weaver MD, Portes WJ. Local streptokinase infusion for superior mesenteric artery thromboembolism. AJR 1983; 140: 771–2.
62. Fischer CP, Konnak JW, Cho KJ, Eckhauser FE, Stanley JC Renal artery embolism: therapy with intra-arterial streptokinase infusion. J Urol 1981; 125: 402–4.
63. Steckel A, Johnston J, Fraley DS, Bruns FJ, Segel DP, Adler S. The use of streptokinase to treat renal arterial thromboembolism. Am J Kidney Dis 1984; 4: 166–70.
64. Andrews JC, Griggs TJ, Ensminger WD, Gyves JW, Cho KJ. Local thrombolytic therapy for hepatic artery thrombosis following chemotherapy infusion catheter placement. Invest Radiol 1987; 22: 467–71.
65. Pritchard SL, Culham JAG, Rogers PCJ. Low-dose fibrinolytic therapy in infants. J Pediatr 1985; 106: 594–8.
66. Cocke TB, Burgos-Calderon RA, Gonzalez FM. The use of streptokinase infusions for arteriovenous shunt declotting. Trans Am Soc Artif Intern Organs 1970; 16: 292–9.
67. Gagnon RM, Beaudet R, Lemire J, Carignan L, Guimond C, Cousineau R. Streptokinase thrombolysis of a chronically thrombosed mitral prosthetic valve. Cathet Cardiovasc Diagn 1984; 10: 5–10.
68. Luluaga IT, Carrera D, d'Oliveira J, et al. Successful thrombolytic therapy after acute tricuspid-valve obstruction. Lancet 1971; 1: 1067–8.
69. Roudaut M-FL, Ledain L, Roudaut R, Besse P, Boisseau MR. Thrombolytic treatment of acute thrombotic obstruction with disk valve prostheses: experience with 26 cases. Semin Thromb Hemost 1987; 13: 201–5.
70. Baglin JY, Diébold B, Hénin D, et al. Thrombose de prothése valvulaire: embolic cérébrale mortelle lors du traitement thrombolytique. Arch Mal Coeur 1983; 76: 1077–80.
71. Kremer P, Fiebig R, Tilsner V, Bleifeld W, Mathey DG. Lysis of left ventricular thrombi with urokinase. Circulation 1985; 72: 112–8.
72. Keren A, Medina A, Gottlieb S, Banai S, Stern S. Lysis of mobile left ventricular thrombi during acute myocardial infarction with urokinase. Am J Cardiol 1987; 60: 1180–1.
73. Hecker SP, Zweng HC Central retinal artery occlusion successfully treated with plasmin. JAMA 1961; 176: 1067–9.
74. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7: 135–42.
75. Nenci GG, Gresele P, Taramelli M, Agnelli G, Signorini E. Thrombolytic therapy for thromboembolism of vertebrobasilar artery. Angiology 1983; 34: 561–71.
76. Del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986; 17: 595–607.
77. Kudo S, Chuang VP, Wallace S, Mir S, Bechtel W, Carrasco CH. Transcatheter thrombolysis in cancer patients. Cardiovasc Intervent Radiol 1985; 8: 1–7.
78. Sloan MA. Thrombolysis and stroke: past and future. Arch Neurol 1987; 44: 748–68.
79. Jan K-M, Chien S, Bigger JT Jr. Observations on blood viscosity changes after acute myocardial infarction. Circulation 1975; 51: 1079–84.
80. Gordon RJ, Snyder GK, Tritel HJ, Taylor WJ. Potential significance of plasma viscosity and hematocrit variations in myocardial ischemia. Am Heart J 1974; 87: 175–82.
81. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987; 2: 871–4.
82. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850–5.
83. Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987; 317: 1613–8.
84. Fratantoni JC, Ness P, Simon TL. Thrombolytic therapy: current status. N Engl J Med 1975; 293: 1073–8.
85. Sherry S, Gustafson E. The current and future use of thrombolytic therapy. Annu Rev Pharmacol Toxicol 1985; 25: 413–31.
86. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985; 6: 556–85.
87. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl J Med 1979; 301: 797–802.
88. Stampfer MJ, Goldhaber SZ, Yusuf S, Peto R, Hennekens CH. Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. N Engl J Med 1982; 307: 1180–2.
89. Rentrop P, Blanke H, Karsch KR, et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979; 2: 354–63.
90. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction: a 12-month follow-up report. N Engl J Med 1985; 312: 1073–8.
91. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol 1986; 7: 717–28.
92. Kennedy JW, Gensini GG, Timmis GC, Maynard C. Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography. Am J Cardiol 1985; 55: 871–7.
93. Weinstein J. Treatment of myocardial infarction with intracoronary streptokinase: efficiency and safety data from 209 United States cases in the Hoechst-Roussel registry. Am Heart J 1982; 104: 894–8.
94. Marder VJ, Francis CW. Thrombolytic therapy for acute transmural myocardial infarction: intracoronary versus intravenous. Am J Med 1984; 77: 921–8.
95. Furberg CD. Clinical value of intracoronary streptokinase. Am J Cardiol 1984; 53: 626–7.
96. Schröder R, Neuhaus K-L, Leizorovicz A, Linderer T, Tebbe U. A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity, J Am Coll Cardiol 1987; 9: 197–203.
97. Kennedy JW, Martin GV, Davis KB, et al. The Western Washington Intravenous Streptokinase in acute myocardial infarction randomized trial. Circulation 1988; 77: 345–52.
98. ISIS Steering Committee. Intravenous streptokinase given within 0–4 hours of onset of myocardial infarction reduced mortality in ISIS-2. Lancet 1987; 1: 502.
99. Yusuf S. Results of intravenous streptokinase on mortality and reinfarction: an overview of 31 randomized trials. In: Kakkar VV, Kennedy JW, Mettinger JL, eds. Coronary thrombolysis: current answers to critical questions. London: Current Medical Literature (in press).
100. Smith B, Kennedy JW. Thrombolysis in the treatment of acute transmural myocardial infarction. Ann Intern Med 1987; 106: 414–20.
101. Schreiber TL, Miller DH, Silvasi DA, Moses JW, Borer JS. Randomized double-blind trial of intravenous streptokinase for acute myocardial infarction. Am J Cardiol 1986; 58: 47–52.
102. Gold HK, Leinbach RC, Garabedian HD, et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73: 347–52.
103. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545–9.
104. Taylor GJ, Mikell FL, Moses W. Intravenous versus intracoronary streptokinase therapy for acute myocardial infarction in community hospitals. Am J Cardiol 1984; 54: 256–60.
105. Hartmann JR, McKeever LM, Bufalino VB, Amirparvis F, Scanlon PJ. Intravenous streptokinase in acute myocardial infarction: experience of community hospitals served by paramedics. Am Heart J 1986; 111: 1030–4.
106. Topol EJ, Fung AY, Kline E, et al. Safety of helicopter transport and out-of-hospital intravenous fibrinolytic therapy in patients with evolving myocardial infarction. Cathet Cardiovasc Diagn 1986; 12: 151–5.
107. Jan K-M, Reinhart W, Chien S, et al. Altered rheological properties of blood following administrations of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction. Circulation 1985; 72: Suppl 111: 111–417. abstract.
108. Arntz R, Heitz J, Schäfer H, Schröder R. Hemorheology in acute myocardial infarction: effects of high dose intravenous streptokinase. Circulation 1985; 72: Suppl 111: 111–417. abstract.
109. Haber E. In vivo diagnostic and therapeutic uses of monoclonal antibodies in cardiology. Annu Rev Med 1986; 37: 249–61.
110. Sturzebecher J, Richter M, Markwardt F. Stable achéal y 1-derivatives of tissuetype plasminogen activator. Thromb Res 1987; 47: 699–703.
111. Collen D, Stassen JM, Stump DC, Verstraete M. Synergism of thrombolytic agents in vivo. Circulation 1986; 74: 838–42.
112. Collen D, Stump DC, Van de Werf F. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. Am Heart J 1986; 112: 1083–4.
113. Rajagopalan S, Gonias SL, Pizzo SV. A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. J Clin Invest 1985; 75: 413–9.
114. Robbins KC, Boreisha IG. A covalent molecular weight 92,000 hybrid plasminogen activator derived from human plasmin fibrin-binding and tissue plasminogen activator catalytic domains. Biochemistry 1987; 26: 4661–7.
115. Collen D. Molecular mechanism of action of newer thrombolytic agents. J Am Coll Cardiol 1987; 10: Suppl B: 11B–15B.
116. Intravenous β-blockade during acute myocardial infarction. Lancet 1986; 2: 79–80.
117. Werns SW, Shea MJ, Driscoll EM, et al. The independent effects of oxygen radical scavengers on canine infarct size: reduction by Superoxide dismutase but not catalase. Circ Res 1985; 56: 895–8.
118. Rich MW. TPA: is it worth the price? Am Heart J 1987; 114: 1259–61.
119. Hopkins LE, Crabbe SJ, Chase SL. Determination of differences in length of stay (LOS) in patients receiving thrombolytic versus conventional therapy for treatment of acute myocardial infarction (AMI). Am Soc Hosp Pharm (in press).
120. Topol EJ, Burek K, O'Neill WW, et al. A prospective randomized controlled trial of early hospital discharge 3 days after myocardial infarction in the reperfusion era: preliminary results. Circulation 1987; 76: Suppl IV: IV–122. abstract.
121. Laffel GL, Fineberg H, Braunwald E. A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. J Am Coll Cardiol 1987; 10: Suppl B: 79B–90B.